ALA-ALA-PHE-CHLOROMETHYLKETONE TFA

AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research[1].

Signaling Pathways >> Metabolic Enzyme/Protease >> Ser/Thr Protease

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

AAF-CMK (0-20 μM; 24 h) shows potentiated antitumor effects of U937 leukemia cells in combination with TRAIL or TNF[1]. AAF-CMK (20 μM; 24 h) increases TNF- and TRAIL-induced U937 cell apoptosis[1]. Cell Viability Assay[1] Cell Line: U937 human promonocytic leukemia cells Concentration: 0-20 μM Incubation Time: 24 h Result: Resulted in the potentiation of growth inhibitory cytostatic effects of TRAIL as well as TNF. Apoptosis Analysis[1] Cell Line: U937 human promonocytic leukemia cells Concentration: 20 μM Incubation Time: 24 h Result: Increased the percentage of apoptotic cells to 55.8% in combination with TRAIL. Increased number of cells with characteristic apoptotic morphology in groups treated with AAF-CMK and both TRAIL or TNF compared to each group treated alone.